Effect of patient age on response to nebulised salbutamol or ipratropium bromide Source: Annual Congress 2012 - Going with the flow: assessment and evaluation of airway function and its role in patient management Year: 2012
A comparison of early bronchodilating responses of Salbutamol, Ipratropium bromide, and the combination of Ipratropium bromide-Salbutamol in stable patients with COPD or asthma Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002
Lung function response to budesonide and ipratropium bromide in COPD patients who continue smoking Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002
Reversibility effects of ipratropium bromide and terbutalin sulphate in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 72s Year: 2001
Pulmonary function and bronchodilator response to albuterol, ipratropium bromide and association of albuterol and ipratropium bromide in children with cystic fibrosis (CF) Source: Eur Respir J 2003; 22: Suppl. 45, 229s Year: 2003
Monitoring of nasal permeability during the treatmrnt of patients with overlap syndrome with combined broncholytic drug (ipratropium bromide + salbutamol) Source: Eur Respir J 2001; 18: Suppl. 33, 216s Year: 2001
Cardiopulmonary effects of inhaled ipratropium bromide and its combination with fenoterol in patients with bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 58s Year: 2002
Evaluation of bronchodilator response to single dose tiotropium bromide Source: Eur Respir J 2004; 24: Suppl. 48, 504s Year: 2004
Nonbronchial effects of ipratropium bromide: is there interference with micturation? Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001
Influence of higher than conventional doses of salbutamol or ipratropium bromide on bronchodilation induced by a regular treatment with tiotropium in patients suffering from stable COPD Source: Eur Respir J 2007; 30: Suppl. 51, 356s Year: 2007
The bronchodilator response to ipratropium is not affected by regular β-agonist use Source: Eur Respir J 2005; 26: Suppl. 49, 123s Year: 2005
Bronchodilator/bronchoprotective effects of aclidinium bromide, a novel long-acting anticholinergic: a phase I study Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007
Sleep architecture in COPD patients during salmeterol versus ipratropium bromide treatment Source: Eur Respir J 2004; 24: Suppl. 48, 113s Year: 2004
Low systemic exposure to aclidinium bromide, a novel long-acting anticholinergic, after multiple doses Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a phase II study Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Airway tone during exercise in healthy subjects: effects of salbutamol and ipratropium bromide Source: Eur Respir J 2003; 22: Suppl. 45, 89s Year: 2003
Improved delivery of fenoterol plus ipratropium bromide using Respimat(R) compared with a conventional metered dose inhaler Source: Eur Respir J 2001; 17: 225-232 Year: 2001
Six months treatment with salmeterol or ipratropium bromide improves effort tolerance and reduces dyspnoea but does not have any effect on lung function in COPD Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002
Comparison of nebulized ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation in children Source: Eur Respir J 2004; 24: Suppl. 48, 167s Year: 2004
Does intraocular pressure change due to delivery method of ipratropium bromide treatment in stabil COPD patients? Source: Eur Respir J 2001; 18: Suppl. 33, 265s Year: 2001